HealthTap Joins LillyDirect to Expand Access to Primary Care–Led Diabetes Treatment
HealthTap is now offering virtual primary care for patients with diabetes on LillyDirect, becoming the platform’s first primary care provider.
Over-the-Counter CGMs Are Here — But Do They Really Make Sense for Non-Diabetics?
Over-the-counter continuous glucose monitors have been available for people with and without diabetes for more than a year now — but the data they collect doesn’t seem to be as useful for nondiabetic users, according to new research from Mass General Brigham.
Beyond IVF: How We’re Revolutionizing Women’s Fertility Health
Dr. Asima Ahmad addresses the challenges multinational employees face when trying to provide fertility benefits.
The Future of Glucose Monitoring: Why Blood-Based Measurements Matter
Today, people living with diabetes have several ways of monitoring glucose levels, whether through finger pricks or CGMs. Both ways of measuring glucose levels have benefits and limitations.
Priority Health Teams Up with Virta Health for Diabetes, Weight Loss Support
Priority Health has partnered with Virta Health to offer a suite of diabetes and weight management solutions to its employer clients.
Why Is Medtronic Spinning Off Its Diabetes Business?
Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, consumer-oriented segment of its business, while also giving the diabetes unit more room to focus and compete in its own crowded market.
Aeroflow Health Unveils New Diabetes Management Program
Aeroflow Health has launched a new diabetes program that offers educational content on diabetes management, medical nutrition therapy and more.
Fixing Primary Care: How AI Is Solving the EHR Problem & Admin Overload
Kyna Fong joins us and shares how AI in being deployed in their platform.
The Role of Medication Delivery in Non-Adherence
For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.
Medicare Part D Spending on 10 Diabetes Drugs Hit $35.8B in 2023
Medicare Part D spending on 10 diabetes drugs increased 364% between 2019 and 2023.
Prioritizing CKD Screening Guidelines is Imperative to Combat Global Health Crisis
The consequences for not prioritizing new guidelines for CKD screening have a devastating impact on population health by increasing the global mortality rate and driving higher healthcare costs.
Food as Health: Shifting from Treatment to Prevention of Diet-Related Disease
Overcoming the systemic, structural and cultural issues that lead to poor nutrition is complex, making it even more essential for both private and public investment in food as health programs and policies that have been shown to be effective.
Where AI Has The Most Potential For Clear ROI
Sezin Palmer talks about where AI has the most potential for ROI.
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.
Dexcom Adds Generative AI Platform to Its Over-the-Counter CGM
Dexcom recently became the first medical device company to embed generative AI into a continuous glucose monitor. Adding generative AI to the company’s Stelo glucose monitor will give users more personalized recommendations about how to improve their metabolic health, said Dexcom COO Jake Leach.
Closing America’s Diabetes Divide: A $412 Billion Opportunity to Transform Diabetes Care
By addressing each community’s unique needs with tailored, culturally responsive care and cross-sector collaboration, we can empower healthcare providers to drive lasting, equitable outcomes.
CGMs Aren’t Just for People with Diabetes Anymore, Dexcom COO Says
This week at HLTH, Dexcom COO Jake Leach discussed Stelo, his company's new product. Stelo is an over-the-counter continuous glucose monitor meant for all adults who don't take insulin.
Improved Access to CGM Data Empowers Providers and Patients to More Effectively Partner on Diabetes Management
Continuous Glucose Monitoring tools are revolutionizing the way diabetes is managed, offering unparalleled benefits for both healthcare providers and patients. By providing continuous, accurate data, CGM is especially useful for remote monitoring, enabling timely interventions and leading to better user health.